INTS Stock — Intensity Therapeutics Inc.: Cash, EV, Pipeline

Share price

$4.11

Market cap

$13.4M

Cash

$9.5M

Enterprise value

$3.9M

Balance sheet

Cash	$9.5M
Debt	$0.0M
Net cash	$9.5M
Enterprise value	$3.9M
Basic shares	2.9M shares
Fully diluted shares	4.0M shares
Fully diluted market cap	$16.4M
Cash per share	$3.29

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading INTS daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jan 12 - Feb 23	INT230-6	Phase 3	Sarcoma,Soft Tissue	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

INT230-6

Phase 3 · Active Modality: intratumoral injection (cisplatin, vinblastine, SHAO amphiphilic molecule)

Partnerships Swiss Cancer Institute (SAKK) collaboration for INVINCIBLE-4

Indications

soft tissue sarcoma (Phase 3)
triple-negative breast cancer (Phase 2)

Catalysts

— Q3 2026

Status note INVINCIBLE-3 Phase 3 paused March 2025 due to funding constraints; limited US enrollment resumption planned Q3 2026; INVINCIBLE-4 Phase 2 enrollment resumed March 2026 after protocol amendment; no discontinuation disclosed.

Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	INT230-6
Lead indication	Sarcoma,Soft Tissue
Lead phase	Phase 3
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06263231	Phase 3	Recruiting	Sponsor	INTS	—	Sarcoma,Soft Tissue	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Intensity Therapeutics, Inc. on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

INTS — Intensity Therapeutics Inc.